- Home
- NUW vs SIGA Comparison
NUW vs SIGA Comparison
Compare NUW & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUW | SIGA |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.9M | 309.8M |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NUW | SIGA |
|---|---|---|
| Price | $13.98 | $3.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.8K | ★ 677.8K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $224.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.50 | $3.10 |
| 52 Week High | $14.70 | $9.62 |
Technical Indicators
Market Signals| Indicator | NUW | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 31.48 | 28.62 |
| Support Level | $13.86 | N/A |
| Resistance Level | $14.47 | $4.84 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 7.02 | 13.46 |
Price Performance
Historical ComparisonAbout NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.